Serina Therapeutics Reports $6.9 Million Net Loss in Q1 2026, Cash Reserves Increase to $24.5 Million

Serina Therapeutics, Inc. reported a net loss of $6.9 million for the first quarter of 2026, compared to a net loss of $4.8 million for the same period in 2025. The company's total operating expenses increased to $6.3 million from $5.9 million year-over-year, driven primarily by higher research and development costs, which rose to $3.2 million from $3.0 million. General and administrative expenses also saw a slight increase, totaling $3.1 million compared to $2.9 million in the prior year. The increase in expenses reflects the company's ongoing investment in its clinical programs and operational infrastructure.

In terms of financial position, Serina's cash and cash equivalents surged to $24.5 million as of March 31, 2026, up from $3.1 million at the end of 2025. This increase was largely attributed to a successful private placement in March 2026, which generated approximately $21.2 million in gross proceeds. The company also reported a significant rise in total current assets, which reached $26.5 million, compared to $6.1 million at the end of the previous fiscal year. This financial boost is critical as the company continues to navigate its clinical development programs and operational needs.

Operationally, Serina has made strides in advancing its lead product candidate, SER-252, which is designed for the treatment of advanced Parkinson's disease. The company has initiated a Phase 1b clinical study, with the first patient dosed in February 2026. The company’s research and development efforts are supported by a growing workforce, with an increase in employee headcount contributing to higher personnel costs. As of March 31, 2026, the company had 12,047 weighted-average shares of common stock outstanding, reflecting its ongoing capital-raising activities.

Looking ahead, Serina Therapeutics faces substantial challenges, including the need for additional financing to support its operations and product development. The company has expressed concerns regarding its ability to continue as a going concern, given its history of operating losses and the anticipated need for further capital to fund its clinical trials and operational expenses. Management has indicated that it will continue to seek funding through equity offerings, debt financing, or strategic collaborations, but acknowledges the uncertainty surrounding its ability to secure such financing on favorable terms.

In summary, while Serina Therapeutics has made progress in its clinical development and financial position, it continues to face significant operational and financial challenges. The company’s future performance will depend on its ability to successfully advance its product candidates through clinical trials and secure the necessary funding to support its ongoing operations.